Geert-Jan Mulder

Managing Partner at Forbion

Speaker

Geert-Jan Mulder MD, is one of the co-founding Managing Partners at Forbion and led the firm’s investments of several portfolio companies including Mariana (sold to Novartis in 2024), Sanifit (sold to Vifor in 2021), KaNDy Therapeutics (sold to Bayer in 2020), Enterprise Therapeutics (sold to Roche in 2020), Promedior (sold to Roche in 2020), Exsosome (sold to Bio-Techne in 2018), bluebirdbio (IPO on Nasdaq 2013: BLUE), Acorda (IPO on Nasdaq 2006: ACOR), PanGenetics (sold to Abbott in 2009) and Transave (reverse-merged with Insmed, listed on Nasdaq in 2010: INSM). In this capacity, Geert-Jan has authored and co-authored several scientific publications from Forbion and Forbion-portfolio companies.

Before joining the venture industry in 2001, Geert-Jan spent several years in the pharmaceutical industry in clinical development and global medical marketing for Searle (now Pfizer) and Byk Gulden (now Takeda). Geert-Jan received his Medical Degree from the University of Utrecht (NL) and spent two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht.